Purpose: Only small and short-term studies have evaluated statins in relation to changes in heart structure. We estimated the association between new statin use and 10-year remodeling of the left ventricle.
| INTRODUCTION
Heart failure (HF) is a common 1 clinical syndrome characterized by structural and functional impairment of the left ventricle. 2 With high treatment costs due to repeat hospitalization, HF is associated with an increasingly high level of patient morbidity over time. Among many treatments explored for HF, statins (ie, HMG-CoA reductase inhibitors) have been evaluated in both primary and secondary prevention. While an approximate 10% reduction in the risk of HF hospitalization has been shown in meta-analyses of statin primary and secondary prevention trials, 3, 4 the mechanism of action is unclear.
These agents may slow or reduce the cardiac remodeling, 5 with some evidence suggesting a beneficial effect of statins on structure and function. 6, 7 Recent clinical guidelines have increased the number of statineligible individuals. 8 Those recommended statins may be young and expected to take these drugs for extended periods. 9, 10 Understanding the potential benefits and harms of long-term treatment with statins is essential for clinical decision making. Among other side effects, there is evidence that statins may cause myopathy, more severe musculoskeletal dysfunction, 11 and diabetes. 12, 13 While the short-term efficacy of statins is well studied, few investigations have evaluated statins and long-term changes in cardiac structure, especially among healthy individuals. The purpose of this study was to estimate the association of new statin use with 10-year longitudinal changes in structure and function of the left ventricle in a diverse population free of clinical cardiovascular disease (CVD) at baseline. The primary outcomes were left ventricular mass (LVM), an important measure of left ventricular hypertrophy and predictor of cardiovascular events, 14 and mass-to-volume ratio (MVR), a measure of concentric remodeling. 15 2 | METHODS
| Participants
The Multi-Ethnic Study of Atherosclerosis (MESA) has been described previously. 16 In brief, MESA is an ongoing prospective observational cohort study designed to investigate the pathogenesis of cardiovascular disease in 4 racial/ethnic groups, where all participants were free of known CVD at enrollment defined as any previous physician- ascertained and adjudicated by experts in neurology, cardiology, and epidemiology. 16 Cardiac magnetic resonance (CMR) imaging protocols have been described previously 18 and were performed on a subset of MESA participants. Coefficients of variation quantified at exam 1 were small (approximately 6% for LVM and 4% for end-diastolic volume). 18 Changes in CMR pulse sequence technology and software between exams required that exam 1 parameters be adjusted to be comparable to those at exam 5. Calibration was performed with a subset of participants at exam 5 who were imaged using both the original gradient echo and the newer steady-state free precession techniques as well as the different software packages for reading images. 18 A total of 5004 MESA participants (73%) completed the baseline CMR scan and had technically adequate data. The main reasons for not completing scans were ineligibility due to metallic implant or device (7%), inability (14%), mostly due to claustrophobia, refusal (3%), mechanical problems with the scanner (0.4%), and unknown (1%).
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For this investigation, we included all MESA participants free of statin use at baseline and with 2 serial CMR at baseline and 10-year follow-up.
| Statin use
Several variables were defined to summarize statin use. Any statin initiation during study follow-up was the primary exposure, defined as any positive report of a statin on the medication inventory at the second through the fifth clinical exams that occurred at unequal intervals over a 10-year period. Participants with 1 or more missing reports of statin use at a clinical exam (eg, they did not bring medication to the appointment) and no reported statin use at other exams were classified as having unclear or missing statin use.
To summarize statin dose, we estimated the mean daily dose reported during the study period. National drug codes recorded in the medication inventory at each clinical exam were used to group statins into low, moderate, and high dose according to the American
College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol. 8 A new user study design, where the analysis is restricted to medication nonusers at baseline, was selected to increase the likelihood that baseline characteristics were not impacted by current statin use. 20 
| CMR imaging
The primary cardiac measures of interest were the absolute change in left ventricular end-diastolic mass and MVR over the study period, derived from the MESA CMR steady-state free precession readings.
Prior to calculating absolute change, baseline and follow-up LVM were indexed using the allometric height-weight-gender methods described in Brumback et al. 21 Because height and weight changed between baseline and follow-up exams, we indexed baseline LVM by gender and baseline height and weight, and follow-up LVM by gender and follow-up height and weight. We studied body surface Propensity score overlap was visually assessed, and covariate balance between statin initiators and matched non-initiators was evaluated using t tests and with Rubin's B and R statistics. 25 The primary analysis estimated the average treatment effect in the treated from a propensity score-matched (PSM) model 26 of statin initiation using 1-to-1 nearest-neighbor matching within 0.025 caliper of propensity score with replacement. We also modeled the relationship using traditional multivariable linear regression. We ran 3 separate PSM models to evaluate the dose of the initiated statin, using the same group of nonusers of statins as the comparison group. Additional multivariable linear models for statin dose are presented. Two sensitivity analyses tested whether these results were robust to (1) the use of multiple imputation for missing data on covariates and outcomes and (2) inverse probability of censoring weighting to account for any loss to follow-up, as only a subset of participants returned for a follow-up
CMR scan approximately 10 years after baseline. All analyses were completed using Stata version 14.0. The PSM analysis was completed 27 using the psmatch2 Stata module (v4.0.11). A 2-tailed P value less than
.05 was considered statistically significant. We determined that the 95% confidence intervals (CIs) generated with a bootstrapping approach (N = 1000) were conservative compared with those adjusting for large sample variance using the methodology of Abadie and Imbens. Those with unclear or missing statin use did not differ substantially from the population with complete covariates at baseline (N = 4234), though they were slightly more likely to be uninsured (15% vs 10%).
Baseline clinical and demographic characteristics are shown in Table 1 
KEY POINTS
• To date, small and short-term studies have investigated statins and heart structure.
• This study in a large, diverse cohort demonstrated a modest association between statin use and reduced remodeling of the left ventricle.
• Overall findings suggest that a statin effect on cardiac remodeling is not the main mechanism of statin benefit in the primary prevention of heart failure. Table 1 . In the final analysis sample (n = 2389), most statin initiators (76%) started a moderate dose statin as shown in Table S1 . Only 13% of statin initiators used hydrophilic statins (ie, pravastatin or rosuvastatin) during the study period. Further information on statin formulation and dose used during the study are described in Table S2 .
| Unadjusted 10-year change in cardiac indices
Follow-up CMR data were available for 2431 participants (57% of the original sample) after a median of 9.4 years. Of these individuals, 42
experienced an incident MI over the study period. Participants lost to follow-up (N = 682) were generally similar to the population at baseline (N = 4234); they were slightly less likely to be male (45% vs 48%) and more likely to be Hispanic (27% vs 23%), former smokers (38% vs 35%), treated diabetics (12% vs 7%), and taking an angiotensinconverting enzyme inhibitor (14% vs 9%) and had slightly higher mean triglyceride levels (144 vs 129 mg/dL).
Among those with complete follow-up, the unadjusted mean changes in measures of left ventricular structure and function are shown in Table 2 and exclude those who experienced an MI. The average time between CMR scans was similar in statin initiators and non-initiators. Over this time, average mass and volume increased for both groups, while average LVEF declined. In general, indices of mass change were higher among non-initiators.
3.3 | Propensity score matching 
| Association between statin initiation and change in cardiac indices
In the primary PSM analysis, excluding those who experienced an MI, statin initiation was statistically significantly associated with less (Table 3) . Results from traditional multivariate regression, inverse probability of censoring weighted regression, and multiply imputed regression models were similar; all estimates were closer to the null than the estimates from the PSM analysis (Table S3 ).
| Association between statin dose and change in cardiac indices
In the dose stratified PSM analyses, results for LVMI and LVEDV were numerically consistent with a dose response (Table 4 ). There was less progression of LVMI as the statin dose increased, while there was less progression in LVEDV as the dose decreased. Moderate dose statins The PSM models used nearest-neighbor matching within 0.025 caliper with replacement to estimate the average treatment effect in the treated. Propensity scores for statin initiation were derived from a logistic regression using the following at baseline: age, gender, race, smoking status (former, never, and current), body mass index, diabetes status (normal, impaired fasting glucose, untreated diabetes, and treated diabetes), waist circumference, antihypertensive agent use (yes/no for diuretics, calcium channel blockers, beta blockers, angiotensin-converting enzyme inhibitors, and angiotensin type 2 antagonists), systolic and diastolic blood pressure, high-density lipoprotein cholesterol, triglycerides, total cholesterol, intentional exercise defined as moderate and vigorous physical activity total (met-min per week), health insurance status (yes/no), and the Agatston coronary artery calcium score as the ln(score + 1).
*Normal-based confidence intervals were bootstrapped with 1000 repetitions.
were associated with statistically significantly less progression of LVMI relative to never use (−2.50; 95% CI, −4.60 to −0.41, P = .02). Lowdose statins were associated with statistically significantly more decline in LVEF relative to never use (2.35 percentage points; 95% CI, 0.33 to 4.37, P = .02). Results from traditional regression models were similar (Table S4 ).
| DISCUSSION
This investigation demonstrated modest association between new statin use and long-term changes in cardiac structure and function in a diverse population with no clinical CVD at baseline. While there was some evidence for an association between statin use and reduced progression in left ventricular mass, all effect sizes were small. This contrasts with previous studies that have demonstrated larger changes and a growing body of literature on statin pleiotropic effects. Ultimately, findings suggest long-term safety of statins that may include a small cardioprotective effect on heart structure. However, these findings are unlikely to fully explain the protective effects of statins on heart failure hospitalization in statin primary prevention trials (RR, 0.89; 95% CI, 0.67-1.17). 4 The mechanism of the beneficial effect of statins on stroke outcomes is still being elucidated. For example, a recent analysis found that statins reduce microembolic signaling in acute cerebral ischemia attributed to large artery atherosclerosis.
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The cholesterol-independent effect of statins on left ventricular mass is postulated to occur through activity on both cardiomyocytes and fibroblasts, which account for 30% and 70% of the myocardium, respectively. 30 Among cardiomyocytes, statins may prevent or reduce hypertrophy via the inhibition of small GTPase signaling pathways (ie, Rho, Rac, and especially, Ras). 31 In animal models of CVD 32-38 as well as early-stage hypertension 39 and hypercholesterolemia, 40 statins have been shown both to prevent development of cardiac hypertrophy and to induce regression of established hypertrophy. Early observational studies in humans have mostly evaluated current or short-term duration of statin use. 41, 42 Randomized studies of statin use and cardiac structure and/or function have often focused on small populations with cardiovascular diseases including cardiomyopathy, [43] [44] [45] [46] [47] [48] congenital aortic stenosis, 49 and heart failure. Observational studies and trials in populations similar to MESA (Table 5 ) have tended to show much larger magnitudes of LVM regression 42, 56 or reduced progression of LVM 54 than this investigation. In the longest and largest of these studies, the hypertension high risk management trial, drug-treated hypertensive patients randomized to fluvastatin had significantly reduced 2-year progression of LVM compared with placebo-treated patients. 55 However, the hypertension high risk management trial study included a markedly less healthy ; however, these biases may be less concerning because of the new-user design, the subclinical outcome measures, and the adjustment for characteristics that could differ between statin users and nonusers (ie, exercise, health insurance, and other medication use) using the PSM approach.
| CONCLUSION
We found modest associations between statin use and long-term changes in indices of cardiac remodeling, when accounting for age, sex, race, and other cardiovascular risk factors. Results are consistent with literature suggesting that an effect on cardiac remodeling is not likely the main mechanism of statin benefit in primary prevention of HF. The results may be consistent with short-term or modest doserelated effects of statins on cardiac structure; however, these findings suggest that there is minimal long-term effect in the primary prevention clinical setting. Future long-term studies may elucidate the causal relationship between statins and heart failure outcomes.
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The majority of these studies were not designed to detect differences between statins and placebo for indexed left ventricular mass. The estimates are derived and presented to inform a comparison of the magnitude of the effect.
*This value is estimated from the change in grams. It assumes body surface area remains constant and uses DuBois' formula to calculate body surface area from BMI, weight, and height.
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